Becton Dickinson (NYSE:BDX) shares tumbled 2.74% in pre-market trading Monday after the medical technology company reported first-quarter results that beat analyst expectations but issued disappointing full-year guidance. The company posted adjusted earnings of $2.91 per share, topping estimates of $2.81, while revenue climbed 1.6% to $5.3 billion, exceeding the $5.15 billion consensus.

Despite the quarterly beat, investors focused on BD's fiscal 2026 adjusted earnings guidance of $12.35 to $12.65 per share, significantly below the analyst consensus of $14.94. The guidance reflects the impact of BD's Biosciences and Diagnostic Solutions business combination with Waters Corporation, which closed on the earnings announcement day. The company maintained its fiscal 2026 revenue growth guidance of low single-digit growth on a foreign currency neutral basis.

BD's Connected Care segment showed the strongest performance with 5.5% reported growth, while the BD Interventional segment grew 5.8%. The Life Sciences segment, which is being separated, declined 8.3%. CEO Tom Polen noted the company delivered stronger-than-expected first-quarter performance through disciplined execution and accelerated commercial initiatives across key end markets.